Related Experiment Video
Updated: Jul 18, 2026
06:06
Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
Published on: September 11, 2020
Macrolide and ketolide resistance with Streptococcus pneumoniae
1Clinical Microbiology Laboratories, University of Iowa Hospital and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA. gary-doern@uiowa.edu
The Medical Clinics of North America
|November 23, 2006
Summary
Macrolide resistance in Streptococcus pneumoniae threatens treatment options. Ketolides, like telithromycin, offer a solution by overcoming common resistance mechanisms in North America.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Macrolide antimicrobials are crucial for treating Streptococcus pneumoniae infections.
- Emerging macrolide resistance in S. pneumoniae compromises clinical efficacy.
- This resistance necessitates the development of alternative antimicrobial agents.
Purpose of the Study:
- To review the current status of macrolide and ketolide resistance in Streptococcus pneumoniae in North America.
- To highlight the impact of antimicrobial resistance on treatment strategies for pneumococcal infections.
Main Methods:
- Literature review of studies on macrolide and ketolide resistance patterns.
- Analysis of resistance mechanisms in Streptococcus pneumoniae.
- Focus on data from North American clinical settings.
Main Results:
- Significant macrolide resistance in S. pneumoniae has been observed.
- Ketolides, such as telithromycin, demonstrate activity against common macrolide-resistant strains.
- Understanding resistance is key to effective antimicrobial stewardship.
Conclusions:
- Macrolide resistance poses a significant challenge for treating S. pneumoniae infections.
- Ketolides represent a promising therapeutic option to overcome existing resistance.
- Continued surveillance of antimicrobial resistance is essential for public health.
Related Concept Videos
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
01:14Atypical Pneumonia
Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...
01:30Development of Antibiotic Resistance
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
01:29Pneumonia I: Introduction
Pneumonia is an infection of the lower respiratory tract that leads to inflammation of the lung parenchyma, often resulting in the accumulation of inflammatory exudate in the alveoli and airways. Unlike the watery, low-protein fluid exudate in pulmonary edema, the exudate in this case is a thick fluid rich in immune cells, proteins, and debris produced during infection and inflammation.This impairs gas exchange and can lead to consolidation of lung tissue. The infection may be caused by a...
01:30Pneumonia I: Introduction
Pneumonia is an acute respiratory infection that targets the lungs, specifically the alveoli. These tiny air sacs, essential for oxygen exchange, become engorged with pus and fluid, severely hindering breathing, decreasing oxygen absorption, and causing significant pain and discomfort during respiration.
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...
Risk Factors
Various factors influence the likelihood of developing pneumonia. Age plays a crucial role, with infants, children under two, and individuals over 65 at increased risk due to their...